Sign In
Buy NEO
$10.14
+0.0200 (+0.198%)
At Close: Jun 03, 2026
NeoGenomics: Market Punishment Continues, But Looks Justified
01:28pm, Friday, 30'th Sep 2022
NeoGenomics continues to present with heightened downside risk and doesn't warrant inclusion into equity portfolios. NEO shares have been heavily compressed in 2022 as investors unload names with weak
Inivata and Collaborators to Present New Data to Support the Application of RaDaR™ MRD Assay Across Tumor Types at ESMO Congress 2022
02:44am, Wednesday, 07'th Sep 2022
Inivata and Collaborators to Present New Data to Support the Application of RaDaR ™ MRD Assay Across Tumor Types at ESMO Congress 2022
Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2022
02:55pm, Friday, 26'th Aug 2022 Benzinga
Upgrades
B of A Securities upgraded the previous rating for Vtex (NYSE:VTEX) from Neutral to Buy. For the second quarter, Vtex had an EPS of $0.11, compared to year-ago quarter EPS of $0.09. At the mo
Turnaround For This Cancer Genetics Testing Firm Could Take Years, Analyst Says While Downgrading Stock
07:29pm, Monday, 22'nd Aug 2022 Benzinga
Needham has downgraded NeoGenomics Inc (NASDAQ: NEO) from Buy to Hold, citing that NEO's turnaround will likely take several years and believes its recently announced Project Catalyst is only an in
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2022
02:03pm, Monday, 22'nd Aug 2022 Benzinga
Upgrades
William Blair upgraded the previous rating for Foot Locker Inc (NYSE:FL) from Sell to Hold. For the second quarter, Foot Locker had an EPS of $1.10, compared to year-ago quarter EPS of $2.21.
Target To $200? Here Are 5 Other Price Target Changes For Thursday
11:35am, Thursday, 18'th Aug 2022 Benzinga
Raymond James raised the price target on Target Corporation (NYSE: TGT) from $190 to $200. However, Raymond James analyst Bobby Griffin maintained the stock with a Strong Buy. Target shares fell 0.1
Neo Performance Materials Inc. (NOPMF) CEO Constantine Karayannopoulos on Q2 2022 Results - Earnings Call Transcript
08:09pm, Friday, 12'th Aug 2022
Neo Performance Materials Inc. (OTCPK:NOPMF) Q2 2022 Earnings Conference Call August 12, 2022 10:00 AM ET Company Participants Ali Mahdavi - Senior Vice President of Corporate Development and Capital
What 4 Analyst Ratings Have To Say About NeoGenomics
04:02pm, Wednesday, 10'th Aug 2022 Benzinga
NeoGenomics (NASDAQ:NEO) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
1
1
0
0
Last 30D
Company News for Aug 10, 2022
01:40pm, Wednesday, 10'th Aug 2022 Zacks Investment Research
Companies in The News Are: NEO,H,ARMK,AHCO
NeoGenomics, Inc.'s (NEO) CEO Lynn Tetrault on Q2 2022 Results - Earnings Call Transcript
12:36pm, Tuesday, 09'th Aug 2022
NeoGenomics, Inc. (NASDAQ:NEO ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Lynn Tetrault – Interim CEO Charlie Eidson – Director of Investor Relations Bill Bon
NeoGenomics (NEO) Reports Q2 Loss, Tops Revenue Estimates
12:25pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 27.27% and 0.86%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
NeoGenomics (NEO) Reports Q2 Loss, Tops Revenue Estimates
09:47am, Tuesday, 09'th Aug 2022
NeoGenomics (NEO) delivered earnings and revenue surprises of 27.27% and 0.86%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Techne (TECH) Lags Q4 Earnings Estimates
11:55am, Thursday, 04'th Aug 2022 Zacks Investment Research
Techne (TECH) delivered earnings and revenue surprises of -0.49% and 0.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Adma Biologics (ADMA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
02:00pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NeoGenomics (NEO) Expected to Beat Earnings Estimates: Should You Buy?
02:01pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
NeoGenomics (NEO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
